Edition:
United Kingdom

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

66.00EUR
9:47am GMT
Change (% chg)

€-0.56 (-0.84%)
Prev Close
€66.56
Open
€66.04
Day's High
€66.30
Day's Low
€65.86
Volume
20,846
Avg. Vol
384,174
52-wk High
€79.05
52-wk Low
€56.55

Chart for

About

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €11,689.79
Shares Outstanding(Mil.): 194.51
Dividend: 1.15
Yield (%): 1.34

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-UCB To Present Phase 2b Findings For Bimekizumab

* UCB ADVANCES PSORIASIS PIPELINE WITH POSITIVE DATA AT AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD 2018)

16 Feb 2018

BRIEF-UCB Announces That EMA Has Approved Label Change For Cimzia

* LABEL CHANGE MAKING IT FIRST ANTI-TNF FOR POTENTIAL USE IN WOMEN WITH CHRONIC RHEUMATIC DISEASE, DURING PREGNANCY AND BREASTFEEDING Source text : http://bit.ly/2Fe7JUV Further company coverage: (Gdynia Newsroom)

09 Jan 2018

BRIEF-UCB Announces European Medicines Agency Accepts Filing For Evenity

* EUROPEAN MEDICINES AGENCY ACCEPTS FILING FOR EVENITY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Jan 2018

BRIEF-UCB Announces Positive Top Line Results Of Phase 2b Bimekizumab Study

* BIMEKIZUMAB DEMONSTRATES IMPRESSIVE JOINT AND SKIN RESPONSES FOR PSORIATIC ARTHRITIS PATIENTS‍​

20 Dec 2017

BRIEF-UCB Bimekizumab Announces Results For Phase 2b Of BE Agile Study ‍​

* BIMEKIZUMAB ADVANCES WITH SIGNIFICANT RESULTS IN ANKYLOSING SPONDYLITIS PATIENTS‍​

14 Dec 2017

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

06 Nov 2017

BRIEF-UCB 9-month revenue up at 3.3 billion euros, 2017 outlook increased

* 9-MONTH REVENUE INCREASED TO € 3.3 BILLION, BY 9%; MAIN PRODUCTS GREW BY 15% TO € 2.6 BILLION

20 Oct 2017

BRIEF-‍Partners Connected Health and UCB announce epilepsy partnership​

* ‍PARTNERS CONNECTED HEALTH AND UCB ANNOUNCE COLLABORATION TO DEVELOP HEALTHCARE SOLUTIONS TO SUPPORT PEOPLE LIVING WITH EPILEPSY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

11 Oct 2017

BRIEF-UCB anti-epileptic drug Vimpat (Lacosamide) receives EU approval for paediatric use

* ANTI-EPILEPTIC DRUG VIMPAT (LACOSAMIDE) RECEIVES EU APPROVAL FOR PAEDIATRIC USE

21 Sep 2017

BRIEF-UCB's Briviact approved by FDA as monotherapy treatment of partial-onset seizures in adults

* NEW INDICATION FOR BRIVIACT (BRIVARACETAM): UCB'S NEWEST ANTIEPILEPTIC DRUG APPROVED BY FDA AS MONOTHERAPY TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

15 Sep 2017

Earnings vs. Estimates